AN2 Therapeutics' second quarter of 2026 arrived with the company standing at a transition that smaller clinical-stage biopharmas almost never get to make on its own terms. By June 30, the company had three Phase 2 programs either starting up or enrolling, an oral boron chemistry platform with a second development candidate being declared before year-end, and $79.9 million of cash, cash equivalents, and investments that management says will carry operations into 2029. The headline numbers told the same story they have for a decade at a company with no product on the market: a GAAP net loss of $8.2 million for the quarter ($0.18 per share), versus a $6.5 million loss a year earlier, and $18.2 million for the first half ($0.46 per share) versus $17.1 million. The first-look read is "R&D up, loss wider." The second look is the right one. The wider loss is the math of a company deliberately pushing cash into the clinic: research and development expense stepped up to $6.0 million in the quarter (versus $3.2 million a year ago) as three Phase 2 starts hit the spend line at once, while general and administrative expense actually fell to $2.9 million from $4.0 million. The company is funding the broader pipeline out of the cash pile it spent the first half of the year building.
The cash build is the operational story of the quarter. In March 2026 AN2 closed a $37.2 million private placement that, on the cash-flow statement, contributed $22.0 million in net common-stock proceeds and $15.5 million in net pre-funded-warrant proceeds during the six months ended June 30; an additional $1.4 million came in through the company's 2026 at-the-market program. Total financing cash flow for the half was $38.8 million - and the operating cash burn was $19.1 million, which means the company ended the quarter with $44.3 million in cash and equivalents (plus $35.5 million of short- and long-term investments) on a base that started the year at $60.0 million of total cash and investments. That is a textbook clinical-stage transition quarter: stock up, runway extended, three programs live, the next twelve months funded without raising again. The only overhang worth flagging is the 8,741,493 pre-funded warrants at a $0.00001 strike that the company issued as part of the March raise - they are functionally common stock for accounting purposes, and the Q2 weighted-average share count of 44.76 million already includes them.
For a pre-revenue biotech, the operational milestone clock is the multiple. Between now and the end of 2026: the polycythemia vera Phase 2 study (EBO-PV-201) is expected to file its IND in the third quarter and dose its first patients in the fourth; the chronic Chagas Phase 2 of AN2-502998 is expected to start in late 2026; and a second boron-based development candidate, after the ENPP1 oncology candidate declared earlier this year, is expected to be named by year-end. The M. abscessus investigator-initiated Phase 2 is already enrolling, with topline targeted for late 2027. With $237 million of market capitalization at the $6.28 reference price and an enterprise value of roughly $158 million (market cap less cash and investments), the company trades at about 3.0x book value - a quality-and-cash premium for a clinical platform with three Phase 2 starts in one year, but one that depends on those Phase 2 programs beginning to enroll on schedule. The thesis is the pipeline clock, and the watch items are the IND filing, the Chagas Phase 2 initiation, and the second candidate nomination.